NAMS — NewAmsterdam Pharma NV Cashflow Statement
0.000.00%
Last trade - 00:00- $1.73bn
- $1.25bn
- $14.09m
Annual cashflow statement for NewAmsterdam Pharma NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | IFRS | USG | USG | USG |
| Status: | fx Final | Final | Final | Final |
| Net Income/Starting Line | -6.55 | -41.8 | -22.6 | -177 |
| Depreciation | ||||
| Non-Cash Items | 0.349 | 7.8 | 22.9 | 29.8 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -0.602 | 4.47 | 10.4 | 5.87 |
| Change in Prepaid Expenses | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -6.8 | -29.5 | 10.7 | -141 |
| Capital Expenditures | -0.015 | -0.024 | -0.221 | -0.024 |
| Purchase of Fixed Assets | ||||
| Cash from Investing Activities | -0.015 | -0.024 | -0.221 | -0.024 |
| Financing Cash Flow Items | — | 0 | -5.79 | 0 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 12.9 | 84.7 | 392 | 8.91 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 6.11 | 50.5 | 408 | -127 |